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The prevalence of type 2 diabetes has been rapidly rising worldwide. In Korea,
the prevalence of diabetes (95% of which were cases of type 2 diabetes) has inc-
reased from 1% of the general population in the 1970s to 13.5% of men and 10.7%
of women aged 30 years or more in 2000.
1 Chronic kidney disease (CKD) is one
of the major complications of type 2 diabetes, and is the leading cause of end-
stage renal disease (ESRD), accounting for approximately 40% of new cases of
ESRD every year.
2 Early detection and treatment of CKD in patients with type 2
diabetes can prevent or retard the progression to ESRD.
Several studies have reported positive associations between inflammatory
biomarkers and ESRD
3-5 or advanced kidney failure.
6 However, few studies have
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Purpose: Chronic low-grade inflammation may induce chronic kidney disease in
patients with type 2 diabetes. This study investigated the relation between
inflammatory biomarkers and chronic kidney disease in patients with type 2
diabetes, which has not yet been reported in Asian populations. Materials and
Methods: A cross-sectional study was performed in 543 patients recruited from
diabetic clinics for an ongoing, prospective study. Multivariate logistic regression
was used to evaluate the association between inflammatory biomarkers and the
presence of chronic kidney disease (estimated glomerular filtration rate < 60
mL/min per 1.73 m
2 by the simplified Modification of Diet in Renal Disease
equation using plasma creatinine). Results: The risk of chronic kidney disease
increased in the highest quartiles of C-reactive protein (CRP) [multivariate odds
ratio (OR) = 3.73; 95% CI = 1.19-1.70] and tumor necrosis factor-α (multivariate
OR = 4.45; 95% CI = 1.63-12.11) compared to the lowest quartiles after adjust-
ments for age, sex, zinc intake, and other putative risk factors for chronic kidney
disease. Conclusion: Our results suggest that CRP and tumor necrosis factor-α
may be independent risk factors for chronic kidney disease in patients with type 2
diabetes. A causal mechanism of this association should be evaluated in a follow-
up study of Korean patients with type 2 diabetes.
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provided information on the relation between inflammation
and mild to moderate CKD. And to the best of our know-
ledge, only two studies have been performed in patients
with type 2 diabetes
7,8 and no study has been performed in
Asian patients with type 2 diabetes. Type 2 diabetes is consi-
dered a chronic inflammatory condition resulting from
obesity-induced dysregulation of adipocytes, which produce
excessive inflammatory cytokines such as tumor necrosis
factor (TNF-α), interleukin-6 (IL-6), and C-reactive protein
(CRP).
9 This persistent inflammatory state further contri-
butes to insulin resistance
10 and abnormal endothelial vas-
cular reactivity.
11 Chronic inflammation exacerbates kidney
damage through mechanisms of vascular endothelial cell
impairments. On the other hand, adiponectin, secreted by
adipose tissue, is considered to be an important modulator of
insulin sensitivity and its concentration is reduced in patients
with type 2 diabetes and CKD, suggesting its various
protective functions as an anti-diabetic and anti-inflamma-
tory factor.
8,12 Previous studies, however, did not include
both inflammatory and anti-inflammatory biomarkers. In
addition, no attempt to assess dietary intake, which is an
important risk factor for both type 2 diabetes and CKD,
2,13
was made in the aforementioned studies.
Therefore, the objective of the present study was to exa-
mine the relation between the risk of CKD and inflamma-
tory (TNF-α, IL-6, and CRP) and anti-inflammatory
(adiponectin) biomarkers in patients with type 2 diabetes.
Our hypothesis was that an inflammatory biomarker would
be positively associated and an anti-inflammatory biomar-
ker negatively associated with the risk of CKD in patients
with type 2 diabetes. 
Study subjects
All participants were patients with type 2 diabetes who
visited one of two diabetes clinics in Seoul, Korea. For an
ongoing, prospective study of patients with type 2 diabetes,
847 subjects (439 men and 408 women, aged 40-85 years),
without coronary heart disease or cerebrovascular disease,
were randomly selected and interviewed for a baseline
investigation from September 2005 to September 2007. In
the baseline sample, 196 subjects were excluded because
no data were available on their plasma creatinine (n = 131),
body mass index (BMI) (n = 3), or dietary intake (n = 62).
Among the remaining 651 subjects, 27 were excluded due
to insufficient information on their blood parameters, and a
further 81 were excluded as a result of fasting blood glu-
cose < 126 mg/dL or hemoglobin A1C (HbA1C) < 6.5%.
Therefore, a total of 543 Korean patients with type 2 dia-
betes (284 men and 259 women; aged 40-85 years) were
ultimately eligible for this analysis. Written informed con-
sent to participate was obtained from each individual. The
study protocol was approved by the Institutional Review
Board of Yonsei University. 
General characteristics, anthropometric 
measurements, and blood pressure 
All subjects were individually interviewed to obtain infor-
mation about general characteristics such as age as well as
life-style behaviors such as smoking (non-, ex-, or current-)
and regular exercise (yes/no). The duration of diagnosed
type 2 diabetes, calculated by subtracting the year of
diagnosis from the year of baseline survey, was obtained
from a review of the medical record or was self-reported
with the help of an attending endocrinologist. For anthropo-
metric measurements, height was measured with a standio-
meter (Seca Inc., Hamburg, Germany) attached to a wall,
weight was assessed using Inbody 4.0 (Biospace Co., Seoul,
Korea), and BMI (kg/m
2) was calculated. Waist circumfe-
rence was measured with a tapeline (Tanita, Seoul, Korea).
Systolic and diastolic blood pressures were measured after
the patients had rested for 10 min in a sitting position,
using an automatic blood pressure monitor (Biospace Co.,
Seoul, Korea), and were read by the attending endocrino-
logists. Hypertension was defined as a systolic blood pres-
sure (SBP) > 140 mmHG, a diastolic blood pressure (DBP)
> 90 mmHG, or as taking hypertension medication. 
Dietary intake
Graduate students trained in nutrition individually inter-
viewed each subject to assess their food consumption for
the past year, using a food frequency questionnaire, which
included 114 food items and had been previously validat-
ed.
14 The food intake data were analyzed using Can-Pro 3.0
software (Korean Nutrition Society, Seoul, Korea) to deter-
mine nutrient intakes for energy, fat, zinc, vitamin A,
vitamin C, vitamin E, and folate, and were compared to the
Dietary Reference Intakes for Koreans.
15
Biochemical analysis
Blood samples were taken after a minimum 12-hour over-
night fast, collected in EDTA-containing tubes, and centri-
fuged at 3,000 rpm for 20 minutes at 4˚C (Hanil Science
Industrial Co., Ltd, Seoul, Korea). The plasma samples
were stored at -80˚C until analysis. Fasting serum levels of
glucose, cholesterol, triglyceride, high-density lipoprotein
(HDL)-cholesterol, albumin, creatinine, and blood urea
nitrogen (BUN) were measured using an autoanalyzer
(Cobas Mira Roche Autoanalyzer, Hoffmann-La Roche
Ltd., Basel, Switzerland). Low-density lipoprotein (LDL)-
cholesterol and the atherogenic index (AI) were calculated
by employing the following equations described by Frie-
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dewald
16 and Lauer
17: LDL-cholesterol = Total cholesterol
- HDL-cholesterol-(Triglyceride/5) and AI = (Total choles-
terol - HDL-cholesterol)/HDL-cholesterol, respectively.
HbA1C was measured by an HLC-723 G7 analyzer (Toche,
Japan). Serum IL-6, TNF-α, and adiponectin concentra-
tions were determined using enzyme linked immunosor-
bent assay kits (Quantikine, R & D Systems Inc., Minnea-
polis, MN, USA) according to the manufacturer’s instruc-
tions, and were read by an ELISA reader (Spectra Max
340, Molecular Devices, Sunnyvale, CA, USA). The mea-
surement of malonialdehyde, a biomarker of antioxidant
status, was performed using a Lipid Peroxidation Assay kit
(Oxford Biomedical Research, Oxford, MI, USA) accor-
ding to the manufacturer’s instructions. 
Assessment of renal function
The estimation of glomerular filteration rate (GFR) using
serum creatinine concentrations is utilized as an index of
kidney function and is examined in patients with type 2
diabetes to assess for CKD. In the present study, renal
function was estimated by the simplified Modification of
Diet in Renal Disease equation, where GFR (mL/min per
1.73 m
2) = 186.3×[(serum creatinine, mg/dL)
-1.154×(age)
-0.203]
×0.742 (if female). The subjects were classified into a
normal kidney function group (GFR ≥ 60 mL/min per 1.73
m
2) and a CKD group (GFR < 60 mL/min per 1.73 m
2).
18 
Statistical analysis
The data were expressed as means with standard errors (ad-
justed for age and sex) or numbers and percentages. Varia-
bles with skewed distributions were log-transformed before
analysis and back-transformed for presenting within tables.
The differences between subjects with and without CKD
were evaluated using an analysis of covariance (ANCOVA)
test after adjustments for age and sex, or a χ 2 test, as ap-
propriate. To investigate the correlations between blood
glucose indicators and inflammatory markers, a partial
correlation analysis controlling for age and sex was perfor-
med. Multivariable-adjusted logistic analysis was con-
ducted to examine the odds ratio (OR) for CKD across
Table 1. General Characteristics and Nutrient Intakes of Study Groups
Normal   CKD  pvalue
Subjects 488 (89.8) 55 (10.2)
Female (%) 231 (47.3) 28 (50.9) 0.021
Age (yrs) 56.1 ± 0.46 64.6 ± 1.37 < 0.001
Duration of diagnosed type 2 diabetes (yrs) 8.4 ± 0.32 11.1 ± 0.97 0.008
BMI (kg/m
2) 24.6 ± 0.14 24.2 ± 0.43 0.484
Waist circumference (cm) 85.6 ± 0.60 87.9 ± 1.83 0.254
Hypertension 243 (49.7) 35 (63.6) 0.064
Regular exercise 281 (58.1) 34 (54.9) 0.885
Cigarette smoking
Non-smoker 282 (57.8) 33 (60.0) 0.479
Ex-smoker 121 (24.8) 10 (18.1)
Current smoker 85 (17.4)  12 (21.9)
Nutrient intake
Energy (kcal) 2,127.1 ± 36.60 2,037.7 ± 111.71 0.449
Fat (g) 58.7 ± 1.56 62.4 ± 4.76 0.455
Zinc (mg) 11.8 ± 0.25 11.8 ± 0.75 0.974
% below estimated average requirement 52 (10.7) 12 (21.8) 0.025
Vitamin A (µgRE) 1,058.6 ± 28.64 1,047.0 ± 87.43 0.900
% below estimated average requirement 60 (12.3) 8 (14.5) 0.666
Vitamin C (mg) 143.2 ± 3.62 132.3 ± 11.06 0.347
% below estimated average requirement 81 (16.6) 8 (14.5) 0.347
Folate (µg) 355.3 ± 7.17 322.9 ± 21.89 0.162
% below estimated average requirement 218 (44.7) 31 (56.4) 0.116
Vitamin E (mg) 17.5 ± 0.47 17.3 ± 1.44 0.860
% below estimated average requirement 73 (23.2) 16 (29.1) 0.206
CKD, chronic kidney disease; BMI, body mass index.
Values are means  ± SE or n (%). Continuous values were adjusted for age and sex, except for age. Eun-Sil Yeo, et al.
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levels of inflammatory biomarkers continuously as well as
across quartiles of them. The first model was adjusted for
age and sex. The second model was additionally adjusted
for the duration of diagnosed type 2 diabetes, smoking,
regular exercise, hypertension, fasting blood sugar, and zinc
intake. All analyses were performed using SPSS version
12.0 software (SPSS Inc., Chicago, IL, USA). Statistical
significance was defined as p< 0.05.
The general characteristics and nutrient intakes of the 543
subjects with type 2 diabetes are presented in Table 1. Of
these 543 patients, 488 (89.8%) were considered to have
normal kidney function and 55 (10.2%) had CKD. It was
found that the type 2 diabetes patients with CKD were
more likely to be female (p= 0.021), were older (p< 0.001),
had a longer duration of type 2 diabetes (p = 0.008), and
were more likely to have zinc intakes less than the estimated
average requirement (p= 0.025).
For clinical characteristics, levels of GFR were lower (p
< 0.001) and levels of creatinine (p < 0.001) and BUN (p <
0.001) higher in the subjects with CKD compared to those
with normal kidney function (Table 2). Mean concentra-
tions of fasting blood sugar were also greater in the pati-
ents with CKD (p = 0.014). In addition, the subjects with
CKD had greater levels of inflammatory biomarkers such
RESULTS
Table 3. Partial Correlation Coefficients between Indicators of Blood Glucose and Inflammatory Biomarkers 
According to Kidney Function
C-reactive protein
Tumor necrosis 
Interleukin-6 Adiponectin
factor-α
Normal CKD Normal CKD Normal CKD Normal CKD
Fasting blood sugar 0.069 0.403
� 0.018 0.408
� 0.004 0.512* 0.026 - 0.111
HbA1C 0.037 0.453* 0.109 0.458* 0.096 0.452* 0.055 - 0.113
CKD, chronic kidney disease; HbA1C, hemoglobin A1C.
Adjusted for age and sex. 
*p< 0.01.
�p< 0.05 significant by partial correlation analysis.
Table 2.Clinical Characteristics of Subjects According to Kidney Function
Normal  (n = 488) CKD (n = 55) pvalue
Kidney function
GFR (mL/min/1.73 m
2)  98.1 ± 1.41 59.5 ± 4.30 < 0.001
Creatinine (mg/dL) 0.8 ± 0.18 1.5 ± 0.056 < 0.001
Blood urea nitrogen (mg/dL)  15.5 ± 0.21 21.0 ± 0.63 < 0.001
Serum albumin (g/dL) 4.4 ± 0.20 4.3 ± 0.60 0.907
Glucose control
Fasting blood sugar (mg/dL) 166.7 ± 2.48 186.4 ± 7.56 0.014
Hemoglobin A1C (%) 8.4 ± 1.84 8.6 ± 1.90 0.705
Blood lipids
Triglyceride (mg/dL) 142.2 ± 3.82 158.1 ± 11.62 0.196
Total cholesterol (mg/dL) 189.5 ± 1.80 192.7 ± 5.49 0.584
HDL-cholesterol (mg/dL) 49.7 ± 0.61 47.8 ± 1.87 0.339
LDL-cholesterol (mg/dL) 111.4 ± 1.61 113.3 ± 4.93 0.719
Atherogenic index  3.0 ± 0.06 3.2 ± 0.17 0.377
Malondialdehyde (µM/L)  2.7 ± 0.13 2.6 ± 0.369 0.924
Inflammatory biomarkers
C-reactive protein (mg/dL) 2.1 ± 0.34 5.0 ± 1.12 0.013
Tumor necrosis factor-α(pg/mL)   1.1 ± 0.31 1.5 ± 0.95 < 0.001
Interleukin-6 (pg/mL)  1.8 ± 0.11 2.3 ± 0.35 0.158
Adiponectin (µg/mL) 5.9 ± 0.24 7.9 ± 0.74 0.008
CKD, chronic kidney disease; GFR, glomerula filteration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
Values are means ±SE or n (%). Continuous values were adjusted for age and sex. TNF-α, CRP, and Chronic Kidney Disease
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as CRP (p = 0.013) and TNF-α (p < 0.001), as expected,
but they also had higher levels of the anti-inflammatory
biomarker adiponectin (p = 0.008) than the normal sub-
jects, contrary to our expectation. No differences were
found in serum albumin, HbA1C, blood lipid levels, and
IL-6 between the two groups.
Elevated blood glucose levels in patients with type 2
diabetes can affect concentrations of inflammatory biomar-
kers. Partial correlation analysis revealed a significantly
positive correlation between blood glucose indicators and
inflammatory biomarkers (Table 3). CRP, TNF-α, and IL-
6 were significantly positively correlated with fasting blood
sugar and HbA1C. Such a correlation did not exist for adi-
ponectin.
The overall results relating plasma levels of inflamma-
tory biomarkers to the risk of CKD are shown in Table 4.
The OR for CKD was positively associated with conti-
nuous values of CRP (OR = 1.04, 95% CI = 1.01-1.07; p =
0.010) and TNF-α (OR = 1.82, 95% CI = 1.32-2.53; p <
0.001) after adjustments for age and sex. The association
did not change after further adjustments for duration of
type 2 diabetes, smoking, exercise, hypertension, fasting
blood sugar, and zinc intake. For quartiles of these
biomarkers, a positive association existed between CKD
risk and CRP (OR = 3.68, 95% CI = 1.77-10.75; p = 0.014)
and TNF-α (OR = 3.78, 95% CI = 1.45-9.84; p = 0.002)
across the lowest to highest quartiles. Furthermore, these
trends did not change after adjusting other confounders
(OR = 3.73, 95% CI = 1.19-11.70; p = 0.029 for CRP and
OR = 4.45, 95% CI = 1.63-12.11; p = 0.001 for TNF-α).
The OR for CKD tended to slightly increase with conti-
nuous values of adiponetin (OR = 1.06, 95% CI = 1.01-
1.11; p = 0.005), but this trend disappeared when the
values were treated as quartiles. 
From our data we found a strong and graded association
between CRP and TNF-α and the risk of CKD in Korean
patients with type 2 diabetes. Plasma concentrations of
CRP and TNF-α were significantly higher in subjects with
CKD compared to those without CKD, and the risk of
CKD was > 3-fold greater from the lowest to highest quar-
tiles of CRP and TNF-α, respectively. This association
appeared to be independent of other well-known putative
risk factors for CKD such as age, sex, duration of diagnosed
type 2 diabetes, smoking, exercise, having hypertension,
fasting blood sugar concentrations, and zinc intake, based
on multivariable-adjusted logistic analysis. Our results
suggest that high concentrations of CRP and TNF-α may
be an independent risk factor for CKD in Korean patients
with type 2 diabetes.
Our findings are consistent with previously reported
results. In cross-sectional analyses from the Health Profes-
sionals’ Follow-Up Study of U.S. male patients with type
2 diabetes aged 40-75 years, soluble tumor necrosis factor
receptor type 2 was positively associated with the risk of
CKD (GFR < 60 mL/min per 1.73 m
2).
7 In a cross-sectional
study of 23 dialyzed and 16 non-dialyzed chronic renal
failure patients and 28 healthy controls in England, con-
centrations of CRP and TNF-α were elevated in patients
DISCUSSION
Table 4. Multivariable Logistic Regression Odds Ratios (OR) for an Outcome of Calculated GFR < 60 mL/min Per 1.73 m
2 for 
Continuous Values and for Quartile Groups of Blood Inflammatory Biomarkers 
Continuous values Quartile groups
OR ( 95%CI ) P-for-trend Q1 Q2 Q3 Q4 P-for-trend
C-reactive protein
Model 1 1.04 (1.01 - 1.07) 0.010 1 2.16 (0.99 - 1.07) 1.65 (0.99 - 1.07) 3.68 (1.77 - 10.75) 0.014
Model 2 1.04 (1.01 - 1.08) 0.013 1 2.57 (0.78 - 8.50) 2.02 (0.59 - 6.94) 3.73 (1.19 - 11.70) 0.029
Tumor necrosis factor-α
Model 1 1.82 (1.32 - 2.53) < 0.001 1 1.36 (0.47 - 3.90) 1.80 (0.63 - 5.05) 3.78 (1.45 - 9.84) 0.002
Model 2 1.89 (1.33 - 2.67) < 0.001 1 1.32 (0.44 - 3.96) 2.36 (0.81 - 6.93) 4.45 (1.63 - 12.11) 0.001
Interleukin-6
Model 1 1.03 (0.91 - 1.17) 0.148 1 1.14 (0.44 - 2.96) 1.39 (0.53 - 3.70) 1.49 (0.60 - 3.70) 0.195
Model 2 1.06 (0.96 - 1.18) 0.231 1 1.06 (0.40 - 2.80) 1.30 (0.49 - 3.44) 1.18 (0.45 - 3.09) 0.484
Adiponectin 
Model 1 1.05 (0.98 - 1.10) 0.008 1 1.68 (0.64 - 4.41) 1.14 (0.41 - 3.83) 2.26 (0.88 - 5.85) 0.122
Model 2 1.06 (1.01 - 1.11) 0.005 1 1.63 (0.58 - 4.60) 1.31 (0.50 - 3.83) 2.61 (0.95 - 7.16) 0.065
Model 1 is adjusted age and sex. 
Model 2 is adjusted for age (continuous, yrs), sex (male/female), duration of diagnosed type 2 diabetes (continuous, yrs), cigarette smoking status (never, past, and
current), regular exercise (yes/no), hypertension (yes/no), fasting blood sugar (quartile groups), and zinc intake (below estimated average requirement: yes/no).with chronic renal failure as compared to the controls.
19
Also shown in a previous study,
8 serum adiponectin con-
centrations were greater in patients with CKD than in
patients with normal kidney function.
Nonetheless, some studies have shown incompatible
results. Among the U.S. male patients with type 2 diabetes
from the Health Professionals’ Follow-Up Study, no
relation existed between CRP levels and CKD risk (GFR <
60 mL/min per 1.73 m
2).
7 Prior studies have reported a
positive correlation between serum adiponectin levels and
kidney function.
20 Also, from another sub-study of the
Health Professionals’ Follow-Up Study,
8 serum adiponec-
tin concentration was negatively associated with the risk of
CKD (GFR < 60 mL/min per 1.73 m
2); this is unlike our
results in which adiponectin was not associated with CKD
risk although patients with CKD had higher mean adipo-
nectin levels than those without. Some studies have reported
elevated levels of IL-6 in patients with chronic renal failure
9
or in type 2 diabetes patients with nephropathy,
21 but such
a difference was not found in our study. In addition, unlike
findings from other studies showing a positive relation
between serum lipids and the risk of CKD,
7 blood lipid
levels were not different between patients with CKD and
those without CKD in our study.
These inconsistent results may be attributable to dif-
ferences in the ethnic origins of the study populations. In
this regard, ethnic-specific differences in risk factors of
CKD should be considered. For example, none of the
studies mentioned above, except for our current study,
included dietary intake as a confounding factor for analysis.
An intervention study has suggested the beneficial effects
of vitamin C, vitamin E, and zinc on kidney function,
22
which is similar to our results where a greater proportion
of the subjects with CKD had inadequate zinc intakes.
Another possible reason for the incompatible results is the
use of different criteria for CKD. Therefore, a direct com-
parison is not possible due to the many differences in the
study conditions.
Several mechanisms for the effects of CRP and TNF-αon
the risk of CKD have been proposed, although the me-
chanisms leading to the development and progression of
renal injury in type 2 diabetes are not fully understood. CRP,
produced by the liver tissue, and TNF-α, synthesized
primarily by monocytes and macrophages, are cytokines
and sensitive indicators of inflammation. It is now evident
that activated innate immunity and inflammation are related
to the pathogenesis of diabetes.
21 Furthermore, elevated
levels of these inflammatory markers in patients with type 2
diabetes, who have chronic low-grade inflammation, play a
critical role in the development of microvascular diabetic
complications, including CKD, by potentiating endotherial
dysfunction. Epidemiologic studies
13,23 have reported that in
type 2 diabetes patients with CKD who had high blood
glucose levels for a prolonged period of time, poor glycemic
control was markedly associated with a rapid decline in
GFR and increased pro-inflammatory cytokines. Endothelial
dysfunction causes increases in pro-inflammatory cytokines
and anti-inflammatory cytokines.
8
Consistent with our results, a positive correlation between
measures of insulin resistance and plasma concentrations
of CRP
24 and TNF-α
21 was previously reported in patients
with CKD. Fasting blood sugar levels were also greater in
subjects with CKD than in those without (Table 2). Overall,
our data suggest that elevated blood glucose may contribute
to increases in plasma concentrations of CRP and TNF-α,
and tight blood glucose control is a top priority for patients
with type 2 diabetes to prevent and retard the progression
of diabetic complications.
Our study had several limitations that should be addres-
sed in future studies. For example, it specifically focused
on a representative group of Korean patients with type 2
diabetes. Therefore, these results cannot easily be gene-
ralized to other populations or ethnic groups. We observed
an association between plasma concentrations of CRP and
TNF-α and the risk of CKD in a cross-sectional setting.
Therefore, it was not possible to determine whether plasma
concentrations of CRP and TNF-α are a cause or conse-
quence of CKD. The causality between serum levels of
CRP and TNF-α and the risk of CKD should be evaluated
in a follow-up study of the Korean population. In addition,
since the levels of CRP and TNF-α increased in other
cardiac conditions complicating type 2 diabetes and subse-
quent microvascular changes, additional biomarkers
should be employed to clarify their specific direction of
association to CKD. Furthermore, recall bias may have
affected the subjects’ self-reporting of the duration of
diagnosed type 2 diabetes, although the use of a standard
protocol and well-trained interviewers minimized any bias.
This study also had several advantages. To date, no inves-
tigation has examined the association between inflamma-
tory markers and CKD in Asian patients with type 2
diabetes, who have greater risk of CKD, and must be
targeted for its prevention in order to further inhibit the
prolonged development of type 2 diabetes complications
such as ESRD and cardiovascular disease. This study also
showed that elevated levels of CRP and TNF-α in patients
with type 2 diabetes had significant effects on the risk of
CKD after adjustments for putative risk factors for CKD
including dietary intake, which is important but had not
been previously investigated.
In conclusion, our results suggest that high concentra-
tions of CRP and TNF-α may be independent risk factors
for CKD in Korean patients with type 2 diabetes. Large-
scale intervention studies are needed to evaluate whether
Eun-Sil Yeo, et al.
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lowering blood concentrations of CRP and TNF-α reduces
the risk of CKD, and potential benefits of modulating CRP
or TNF-α activity as therapeutic targets appear to exist in
patients with type 2 diabetes.  
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